Invesco Nasdaq Biotechnology ETF IBBQ
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Expense ratio
- 0.19%
- Net assets
- $67.4M
- Holdings
- 261
- 12-month distribution yield
- 1.12%
- Asset class
- Equity
Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund listed on the Nasdaq in the United States, issued by Invesco. Its category is Equity · Global (equity). Its last price was US$35.07 on 20 Oct 2026. Its expense ratio is 0.19% a year, from its prospectus dated 19 Dec 2025. It reported net assets of US$67.37 million as of 31 May 2026. Its latest holdings report lists 261 holdings as of 31 May 2026. Over the last 12 months it paid distributions of US$0.39 a unit, a 12-month distribution yield of 1.12%, paid quarterly.
Fees
- Total annual operating expenses (gross)
- 0.19%
- Net, after fee waivers or reimbursements
- No waiver stated
- Management fee
- 0.19%
- Prospectus date
- 19 Dec 2025
- Filed with the SEC
- 18 Dec 2025
Size and reporting
- Net assets
- $67,373,541
- Total assets
- $80,645,249
- Holdings as of
- 31 May 2026
- Report made public
- 28 Jul 2026 (58 days after the month end)
Top holdings
Largest 25 of 261 positions, as of 31 May 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | Invesco Private Prime Fund | No identifier reported | 14.20% | $9.6M | Short-term investment vehicles (cash funds) | United States | USD |
| 2 | Gilead Sciences, Inc. | US3755581036 | 7.39% | $5.0M | Equity (common) | United States | USD |
| 3 | Vertex Pharmaceuticals Inc. | US92532F1003 | 7.38% | $5.0M | Equity (common) | United States | USD |
| 4 | Amgen Inc. | US0311621009 | 7.10% | $4.8M | Equity (common) | United States | USD |
| 5 | Invesco Private Government Fund | No identifier reported | 5.48% | $3.7M | Short-term investment vehicles (cash funds) | United States | USD |
| 6 | Regeneron Pharmaceuticals, Inc. | US75886F1075 | 5.08% | $3.4M | Equity (common) | United States | USD |
| 7 | Alnylam Pharmaceuticals, Inc. | US02043Q1076 | 3.19% | $2.1M | Equity (common) | United States | USD |
| 8 | Revolution Medicines, Inc. | US76155X1000 | 2.48% | $1.7M | Equity (common) | United States | USD |
| 9 | Biogen Inc. | US09062X1037 | 2.29% | $1.5M | Equity (common) | United States | USD |
| 10 | Illumina, Inc. | US4523271090 | 1.98% | $1.3M | Equity (common) | United States | USD |
| 11 | United Therapeutics Corp. | US91307C1027 | 1.94% | $1.3M | Equity (common) | United States | USD |
| 12 | Royalty Pharma PLC Royalty Pharma PLC, Class A | GB00BMVP7Y09 | 1.90% | $1.3M | Equity (common) | United Kingdom | USD |
| 13 | argenx SE argenx SE, ADR | US04016X1019 | 1.89% | $1.3M | Equity (common) | Netherlands | USD |
| 14 | Insmed Inc. | US4576693075 | 1.83% | $1.2M | Equity (common) | United States | USD |
| 15 | Roivant Sciences Ltd. | BMG762791017 | 1.71% | $1.2M | Equity (common) | Bermuda | USD |
| 16 | Incyte Corp. | US45337C1027 | 1.53% | $1.0M | Equity (common) | United States | USD |
| 17 | Viatris Inc. | US92556V1061 | 1.49% | $1.0M | Equity (common) | United States | USD |
| 18 | Moderna, Inc. | US60770K1079 | 1.48% | $999K | Equity (common) | United States | USD |
| 19 | Guardant Health, Inc. | US40131M1099 | 1.35% | $912K | Equity (common) | United States | USD |
| 20 | Neurocrine Biosciences, Inc. | US64125C1099 | 1.26% | $852K | Equity (common) | United States | USD |
| 21 | Jazz Pharmaceuticals PLC | IE00B4Q5ZN47 | 1.16% | $780K | Equity (common) | Ireland | USD |
| 22 | Ascendis Pharma A/S | DK0060615755 | 1.10% | $740K | Equity (common) | Denmark | USD |
| 23 | Summit Therapeutics Inc. | US86627T1088 | 1.08% | $729K | Equity (common) | United States | USD |
| 24 | Exelixis, Inc. | US30161Q1040 | 1.04% | $703K | Equity (common) | United States | USD |
| 25 | BridgeBio Pharma, Inc. | US10806X1028 | 1.02% | $689K | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 99.87% | |
| Short-term investment vehicles (cash funds) | 19.69% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 103.75% | |
| United Kingdom | 2.73% | |
| Netherlands | 2.49% | |
| Ireland | 1.88% | |
| Bermuda | 1.71% | |
| France | 1.50% | |
| Denmark | 1.23% | |
| Switzerland | 1.18% | |
| Canada | 0.93% | |
| Germany | 0.87% | |
| Cayman Islands | 0.64% | |
| Jersey | 0.15% | |
| Other (6) | 0.50% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 119.56% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Health Care | 79.50% | |
| Health Technology | 1.33% | |
| Technology | 0.70% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
- Paid in the last 12 months
- $0.3910
- 12-month yield
- 1.12%
- Frequency
- Quarterly
- Latest ex-date
- 21 Sep 2026
12-month yield = distributions per unit with an ex-date in the last 12 months ($0.3910) ÷ latest price ($35.07) × 100 = 1.12%. It looks back, so it is not a forecast; special distributions in the window are included.
Why a distribution yield is not the fund's return: yield vs total return
Distribution history table (20 payments)
| Ex-date | Amount per unit |
|---|---|
| 21 Sep 2026 | $0.2300 |
| 22 Jun 2026 | $0.0340 |
| 23 Mar 2026 | $0.0360 |
| 22 Dec 2025 | $0.0910 |
| 22 Sep 2025 | $0.0960 |
| 23 Jun 2025 | $0.0290 |
| 24 Mar 2025 | $0.0400 |
| 23 Dec 2024 | $0.0620 |
| 23 Sep 2024 | $0.0890 |
| 24 Jun 2024 | $0.0510 |
| 18 Mar 2024 | $0.0440 |
| 18 Dec 2023 | $0.0530 |
| 18 Sep 2023 | $0.0410 |
| 20 Jun 2023 | $0.0450 |
| 20 Mar 2023 | $0.0380 |
| 19 Dec 2022 | $0.0420 |
| 19 Sep 2022 | $0.0380 |
| 21 Jun 2022 | $0.0430 |
| 21 Mar 2022 | $0.0380 |
| 20 Dec 2021 | $0.1050 |
Filings and sources
- Form N-PORT report for May 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000072469) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- IBBQ and VT Vanguard Total World Stock Index ETF
- IBBQ and SMH VanEck Semiconductor ETF
- IBBQ and SOXX iShares PHLX SOX Semiconductor Sector Index Fund
- IBBQ and CGDV Capital Group Dividend Value ETF